Design and rationale of GUARDD-US: A pragmatic, randomized trial of genetic testing for APOL1 and pharmacogenomic predictors of antihypertensive efficacy in patients with hypertension

Medicine & Life Sciences

• Pragmatic Clinical Trials 100%
• Pharmacogenetics 80%
• Genetic Testing 73%
• Antihypertensive Agents 64%
• Hypertension 45%
• Blood Pressure 45%
• Pharmacogenomic Testing 21%
• Clinical Decision Support Systems 21%
• Chronic Renal Insufficiency 14%
• Alleles 7%
• Genotype 7%
• Electronic Health Records 5%
• Multicenter Studies 4%
• Primary Health Care 4%
• Cardiovascular Diseases 3%
• Randomized Controlled Trials 3%
• Health 2%